Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Deffered Revenue (2024 - 2025)

Kura Oncology (KURA) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $424.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue rose 67.35% to $424.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $424.9 million, a 67.35% increase, with the full-year FY2025 number at $424.9 million, up 67.35% from a year prior.
  • Non-Current Deffered Revenue was $424.9 million for Q4 2025 at Kura Oncology, up from $268.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $424.9 million in Q4 2025 to a low of $252.5 million in Q2 2025.